EULAV Asset Management’s Novartis NVS Stock Holding History

EULAV Asset Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-47,542	Closed	-$3.62M	–	400
2014 Q1	$3.62M	Hold	47,542	–	–	0.2%	167
2013 Q4	$3.42M	Hold	47,542	–	–	0.19%	177
2013 Q3	$3.27M	Sell	47,542 -446	-0.9%	-$29.5K	0.19%	177
2013 Q2	$3.04M	Buy	+47,988	New	+$3.12M	0.19%	185

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.32% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EULAV Asset Management's NVS Position: Q2 2014 in Review

EULAV Asset Management sold out of Novartis (NVS) in Q2 2014, closing a stake of 47,542 shares — an estimated $3.62M sold.

EULAV Asset Management first reported a position in NVS in Q2 2013 and held it in 4 quarters. The position peaked at $3.62M in Q1 2014. 848 funds tracked by Wall St. Rank hold NVS as of Q2 2014.

EULAV Asset Management reported no remaining Novartis position as of Q2 2014 after selling out during the quarter.
EULAV Asset Management sold 47,542 Novartis shares in Q2 2014, an estimated $3.62M.
EULAV Asset Management first reported a position in Novartis in Q2 2013 and held it in 4 quarters.
EULAV Asset Management's Novartis position peaked at $3.62M in Q1 2014.
848 funds tracked by Wall St. Rank held Novartis as of Q2 2014.

Based on EULAV Asset Management's 13F filing for Q2 2014, filed 30 Jul 2014.